Imagion Biosystems Limited has announced Appendix 4C, Quarterly report for entities subject to Listing Rule 4.7B, for the quarter ended 31 March, 2018.
Read Appendix 4C, Quarterly report for entities subject to Listing Rule 4.7B
Positive independent review sets priority path to market for MagSense® Technology
Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance